TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2848.
Locate Jan Aushadhi KendraClinical Overview
Glimepiride and Pioglitazone is an oral dual-mechanism antidiabetic combination. Glimepiride stimulates rapid beta-cell insulin release, while pioglitazone enhances peripheral insulin sensitivity in skeletal muscle and adipose tissue via PPAR-gamma receptor activation, providing durable glycemic control. Indicated for type 2 diabetes mellitus uncontrolled on monotherapy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with breakfast with a glass of water. Swallow whole. Never skip breakfast.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia, weight gain, peripheral edema, headache, upper respiratory infection. Rare/Severe: Boxed warning: Congestive heart failure; bone fractures in women, and bladder cancer risk.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Pioglitazone can cause or exacerbate congestive heart failure; contraindicated in NYHA class III/IV heart failure. Monitor for rapid, excessive weight gain, dyspnea, and pedal edema. Carry glucose tablets for hypoglycemia.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Metformin Hydrochloride Prolonged-release 500mg + Glimepiride 2mg Tablets
Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.
Glimepiride Tablets 1mg
Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.
Glimepiride Tablets 2mg
Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.
Pioglitazone Tablets 30mg
Pioglitazone Hydrochloride (15 mg, 30 mg) is a thiazolidinedione (TZD) insulin sensitizer on the WHO Model List of Essential Medicines. It acts as a potent, selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptors, modulating the transcription of genes involved in glucose and lipid metabolism, substantially improving insulin sensitivity in skeletal muscle, liver, and adipose tissue, and preserving pancreatic beta-cell mass over time. Indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.